However, apart from an ongoing phase Ib study addressing WEE1 inhibitor AZD1775 combined with olaparib against refractory solid tumors (www.clinicaltrials.gov; NCT02511795), therapeutic potentials of PARP/WEE1 dual blockade and its effect on HR impairment against cancer remain to be revealed. This evidence concerns the gene PARP1 and cancer.